After the discovery and characterization of BRAF mutations in human melanoma, vemurafenib, the first selective inhibitor for mutant BRAF, was developed and evaluated for a treatment option for patients with BRAF-mutated metastatic melanoma. This evidence concerns the gene BRAF and melanoma.